San Bortolo Hospital, Vicenza Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00992134
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Hematology, San Bortolo Hospital, Vicenza | Department of Hematology, San Bortolo Hospital, Vicenza, Italy | Divisione di Ematologia, Ospedale San Bortolo - Vicenza - Italy | San Bortolo Hospital - Vicenza

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5